Cipla Ltd is up for a third straight session today. The stock is quoting at Rs 1666.4, up 1.57% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.52% on the day, quoting at 25144.05. The Sensex is at 82028.18, up 0.48%. Cipla Ltd has gained around 2.11% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 2.22% in last one month and is currently quoting at 23307.95, up 1.99% on the day. The volume in the stock stood at 7.07 lakh shares today, compared to the daily average of 15.52 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 1674.25, up 1.44% on the day. Cipla Ltd is up 44.27% in last one year as compared to a 27.7% jump in NIFTY and a 57.37% jump in the Nifty Pharma index.The PE of the stock is 33.36 based on TTM earnings ending June 24.Powered by Capital Market - Live

Cipla will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live

Cipla Jiangsu was incorporated in China on 8th August 2019 as a joint venture between Cipla (EU) and Jiangsu Xidi Pharmaceuticals Co., (Xidi) for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services. Cipla Jiangsu has set-up a manufacturing facility in China, primarily focused on inhalation respules products. Currently, Cipla EU and Xidi holds 93.0876% and 6.9124% equity interest respectively in Cipla Jiangsu. The said transaction is being carried out in terms of the existing joint venture contract between the parties and will provide Cipla EU with full control and ownership of Cipla Jiangsu. Upon completion of the transaction, Cipla Jiangsu will become a wholly owned step-down subsidiary of the company. The transaction is expected to be completed on or before 15th November 2024. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma company's consolidated net profit jumped 18.27% to Rs 1177.64 crore in Q1 FY25 as against Rs 995.70 crore reported in Q1 FY24. Total revenue from operations grew by 5.77% year on year to Rs 6693.94 crore in the quarter ended 30 June 2024. The counter shed 0.17% to Rs 1,640.45 on the BSE.Powered by Capital Market - Live

Cipla announced that its wholly owned subsidiary in UK, Cipla (EU) has entered into a definitive agreement on 25 September 2024 for purchase of entire 6.9124% equity interest of Jiangsu Xidi Pharmaceuticals Co.(formerly known as Jiangsu Acebright Pharmaceuticals Co.) held in Cipla (Jiangsu) Pharmaceuticals Co., China (Cipla Jiangsu), subsidiary. Cipla Jiangsu was incorporated in China on 8th August 2019 as a joint venture between Cipla (EU) and Jiangsu XiDi Pharmaceuticals Co. (Xidi), for the purpose of manufacturing, selling and distribution of pharmaceutical products, research and development services and analytical development services. Cipla Jiangsu has set-up a manufacturing facility in China, primarily focused on inhalation respules products. Currently, Cipla EU and Xidi holds 93.0876% and 6.9124% equity interest respectively in Cipla Jiangsu. Powered by Capital Market - Live

Cipla will hold a meeting of the Board of Directors of the Company on 3 September 2024.Powered by Capital Market - Live

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma company's consolidated net profit jumped 18.27% to Rs 1177.64 crore in Q1 FY25 as against Rs 995.70 crore reported in Q1 FY24. Total revenue from operations grew by 5.77% year on year to Rs 6693.94 crore in the quarter ended 30 June 2024. The scrip rose 0.37% to close at Rs 1652.40 on Tuesday, 3 September 2024.Powered by Capital Market - Live

The Board of Cipla at its meeting held on 03 September 2024 has approved the change in directorate as under: - M K Hamied (DIN: 00029084), vide letter dated 3 September 2024, has resigned from the position of Vice Chairman and Non-Executive Director of the Company w.e.f. close of business hours of 29 October 2024 due to age and health. - Adil Zainulbhai (DIN: 06646490) and Abhijit Joshi (DIN: 06568584) have been appointed as Additional Directors (Non- Executive) of the Company with effect from 3 September 2024. Powered by Capital Market - Live

Cipla Ltd gained for a fifth straight session today. The stock is quoting at Rs 1650.7, up 1.99% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25240.45. The Sensex is at 82401.53, up 0.32%. Cipla Ltd has risen around 6.89% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 6.75% in last one month and is currently quoting at 22878.05, up 1.61% on the day. The volume in the stock stood at 10.59 lakh shares today, compared to the daily average of 14.77 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1662, up 2.16% on the day. Cipla Ltd is up 31.26% in last one year as compared to a 31.09% spurt in NIFTY and a 54% spurt in the Nifty Pharma index.The PE of the stock is 32.92 based on TTM earnings ending June 24.Powered by Capital Market - Live

Cipla Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1586.85, up 0.77% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.24% on the day, quoting at 24427.1. The Sensex is at 79938.07, up 0.29%. Cipla Ltd has added around 4.59% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has added around 6.42% in last one month and is currently quoting at 22209.55, down 0.12% on the day. The volume in the stock stood at 9.86 lakh shares today, compared to the daily average of 20.21 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1589.5, up 0.76% on the day. Cipla Ltd is up 28.43% in last one year as compared to a 25.69% gain in NIFTY and a 44.93% gain in the Nifty Pharma index.The PE of the stock is 32.02 based on TTM earnings ending June 24.Powered by Capital Market - Live

Cipla Ltd is up for a third straight session today. The stock is quoting at Rs 1574.65, up 1.36% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 24269.55. The Sensex is at 79387.27, down 0.1%. Cipla Ltd has gained around 4.14% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has gained around 7.67% in last one month and is currently quoting at 22036.95, up 0.88% on the day. The volume in the stock stood at 20.32 lakh shares today, compared to the daily average of 18.51 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1572.35, up 0.64% on the day. Cipla Ltd is up 24.38% in last one year as compared to a 23.62% jump in NIFTY and a 41.62% jump in the Nifty Pharma index.The PE of the stock is 31.59 based on TTM earnings ending June 24.Powered by Capital Market - Live